The risk prediction model established in the research, which integrates these serum cytokines (IL‐4 and IL‐17) with relevant clinical risk factors (gender, smoking, and diabetes) and the protective factor HDL‐C, holds the potential to differentiate patients with CAD from those suspected of having CAD but without AMI. This evidence concerns the gene IL17A and diabetes mellitus.